We tried to choose a Medicare Part D plan. We were stymied – STAT
We assumed that choosing a Medicare Part D plan would be a straightforward and easily accomplished chore. We couldn’t have been more wrong.
Related Articles
Trump backs off proposal to slash prescription drug prices by linking them to foreign countries
Trump is backing away from one of his biggest ideas to tackle the high cost of prescription drugs.
Higher insurance costs eat into savings from drug pricing law by more than expected
The savings in the Democratic-passed drug pricing law will be much smaller than expected because of higher insurance costs, the CBO said.
Rwanda to receive experimental vaccines, therapeutics to combat Marburg outbreak
There are currently no licensed vaccines or drugs to prevent or treat Marburg, but experimental versions are heading to Rwanda.
New analysis reveals postpartum sterilization rates are higher among U.S. women with sickle cell
A Johns Hopkins analysis commissioned by STAT shows that the rate of postpartum sterilization is significantly higher in Americans with sickle cell disease than in…
Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug
Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.
Humana tumbles as insurer faces $3 billion hit to revenue over lower Medicare star ratings
The star ratings downgrade could erase most, if not all, of Humana’s profit in 2026.
Key lawmakers pressure Biden to preserve telehealth prescribing of effective addiction treatment
Buprenorphine is relatively safe and reduces the risk of opioid death by 38% compared with those not receiving medication.
JD Vance talked about reinsurance during the VP debate. How does it work?
Vance clarified during Tuesday’s debate that he was referring to “reinsurance regulation” as a way to make health care more affordable
UnitedHealth sues Medicare to reverse downgraded star ratings
UnitedHealth asked a federal judge to block CMS from lowering the insurer’s 2025 Medicare Advantage quality ratings
After a rocky debut for new RSV tools, hopes are high as a new season approaches
After a rocky debut for new RSV tools, hopes are high as a new season approaches.